Exogenous Administration of Low-Dose Lipopolysaccharide Potentiates Liver Fibrosis in a Choline-Deficient l-Amino-Acid-Defined Diet-Induced Murine Steatohepatitis Model.
Amino Acids
/ deficiency
Animals
Biomarkers
Choline Deficiency
/ complications
Diet
/ adverse effects
Disease Models, Animal
Humans
Lipopolysaccharides
/ adverse effects
Liver Cirrhosis
/ diagnosis
Macrophages
/ immunology
Mice
NF-kappa B
/ metabolism
Non-alcoholic Fatty Liver Disease
/ complications
Signal Transduction
Toll-Like Receptors
/ metabolism
NF-κB
choline-deficient l-amino-acid-defined diet
fibrosis
lipopolysaccharide
nonalcoholic steatohepatitis
toll-like receptor
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
03 Jun 2019
03 Jun 2019
Historique:
received:
14
05
2019
revised:
28
05
2019
accepted:
01
06
2019
entrez:
6
6
2019
pubmed:
6
6
2019
medline:
26
11
2019
Statut:
epublish
Résumé
Various rodent models have been proposed for basic research; however, the pathogenesis of human nonalcoholic steatohepatitis (NASH) is difficult to closely mimic. Lipopolysaccharide (LPS) has been reported to play a pivotal role in fibrosis development during NASH progression via activation of toll-like receptor 4 (TLR4) signaling. This study aimed to clarify the impact of low-dose LPS challenge on NASH pathological progression and to establish a novel murine NASH model. C57BL/6J mice were fed a choline-deficient l-amino-acid-defined (CDAA) diet to induce NASH, and low-dose LPS (0.5 mg/kg) was intraperitoneally injected thrice a week. CDAA-fed mice showed hepatic CD14 overexpression, and low-dose LPS challenge enhanced TLR4/NF-κB signaling activation in the liver of CDAA-fed mice. LPS challenge potentiated CDAA-diet-mediated insulin resistance, hepatic steatosis with upregulated lipogenic genes, and F4/80-positive macrophage infiltration with increased proinflammatory cytokines. It is noteworthy that LPS administration extensively boosted pericellular fibrosis with the activation of hepatic stellate cells in CDAA-fed mice. Exogenous LPS administration exacerbated pericellular fibrosis in CDAA-mediated steatohepatitis in mice. These findings suggest a key role for LPS/TLR4 signaling in NASH progression, and the authors therefore propose this as a suitable model to mimic human NASH.
Identifiants
pubmed: 31163617
pii: ijms20112724
doi: 10.3390/ijms20112724
pmc: PMC6600174
pii:
doi:
Substances chimiques
Amino Acids
0
Biomarkers
0
Lipopolysaccharides
0
NF-kappa B
0
Toll-Like Receptors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
N Engl J Med. 2002 Apr 18;346(16):1221-31
pubmed: 11961152
J Gastroenterol Hepatol. 2003 Nov;18(11):1272-82
pubmed: 14535984
Cancer Res. 1992 Sep 15;52(18):5042-5
pubmed: 1516060
Gastroenterology. 2005 Jul;129(1):113-21
pubmed: 16012941
Hepatology. 2006 Feb;43(2 Suppl 1):S99-S112
pubmed: 16447287
Gastroenterology. 2006 May;130(6):1886-900
pubmed: 16697751
J Hepatol. 2007 Oct;47(4):556-64
pubmed: 17459514
Nat Med. 2007 Nov;13(11):1324-32
pubmed: 17952090
Cytokine. 2008 May;42(2):145-151
pubmed: 18304834
World J Gastroenterol. 2008 Nov 21;14(43):6655-61
pubmed: 19034968
Jpn J Cancer Res. 1990 Nov;81(11):1081-4
pubmed: 1979975
J Inflamm (Lond). 2010 Mar 30;7:15
pubmed: 20353583
Nat Immunol. 2010 May;11(5):373-84
pubmed: 20404851
Hepatology. 2010 Nov;52(5):1836-46
pubmed: 21038418
J Hepatol. 2011 Aug;55(2):415-25
pubmed: 21184788
Am J Clin Nutr. 2012 Apr;95(4):892-900
pubmed: 22338037
Am J Physiol Gastrointest Liver Physiol. 2012 Jun 1;302(11):G1310-21
pubmed: 22442158
Cell Metab. 2012 Jul 3;16(1):44-54
pubmed: 22768838
Mol Med. 2012 Dec 06;18:1346-55
pubmed: 22952059
Hepatology. 2013 Jul;58(1):120-7
pubmed: 23401313
Hepatology. 2014 Jun;59(6):2188-95
pubmed: 24375711
World J Gastroenterol. 2014 Jul 14;20(26):8525-34
pubmed: 25024607
Trans R Soc Trop Med Hyg. 2015 Jan;109(1):9-15
pubmed: 25573105
Gastroenterology. 2016 Jan;150(1):11-3
pubmed: 26602217
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
J Lipid Res. 2017 Jan;58(1):178-187
pubmed: 27811231
Dig Dis Sci. 2017 Feb;62(2):396-406
pubmed: 27913996
Hepatol Res. 2017 Nov;47(12):1317-1328
pubmed: 28029729
Immunobiology. 2017 Jun;222(6):786-796
pubmed: 28132721
Cell Mol Gastroenterol Hepatol. 2017 Jan 17;3(3):469-483
pubmed: 28462384
Nat Med. 2017 Jul;23(7):829-838
pubmed: 28604704
Am J Pathol. 2017 Aug;187(8):1800-1813
pubmed: 28711154
Oncotarget. 2018 Jun 19;9(47):28638-28651
pubmed: 29983886
Hepatology. 2019 Mar 29;:null
pubmed: 30924946
Carcinogenesis. 1994 Oct;15(10):2201-6
pubmed: 7955054